AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31385047 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered stents (ePTFE-FEP-covered nitinol stents)
Number of subjects: 120
Study 31385047 — intervention group
Group type: EXPERIMENTAL
Intervention: Covered stents
Number of subjects: 120
Study 31385047 — intervention group
Group type: COMPARATOR
Intervention: Uncovered stents
Number of subjects: 120
Study 29956434 — intervention group
Group type: EXPERIMENTAL
Intervention: Premaquick
Number of subjects: 151
Study 29956434 — intervention group
Group type: COMPARATOR
Intervention: Modified Bishop score
Number of subjects: 151
Study 27051354 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-enriched beverage (1.16 g DHA/day) for 8 weeks
Number of subjects: 15
Study 27051354 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15
Study 27051354 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute exercise
Number of subjects: 15
Study 27051354 — intervention group
Group type: EXPERIMENTAL
Intervention: Training
Number of subjects: 15
Study 27051354 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS-stimulated PBMCs
Number of subjects: 15
Study 25751083 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential Care Transition Module (RCTM)
Number of subjects: 17
Study 25751083 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 17
Study 23824870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fish oil supplementation for 3 weeks
Number of subjects: 87
Study 23824870 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplementation for 3 weeks
Number of subjects: 87
Study 23824870 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fish oil supplementation following a washout period
Number of subjects: 87
Study 23824870 — intervention group
Group type: COMPARATOR
Intervention: Placebo following a washout period
Number of subjects: 87
Study 20668549 — intervention group
Group type: EXPERIMENTAL
Intervention: EchiTAb Plus-ICP (ET-Plus) - initial dose 3 vials
Number of subjects: 400
Study 20668549 — intervention group
Group type: COMPARATOR
Intervention: EchiTAb G (ET-G) - initial dose 1 vial
Number of subjects: 400
Study 20668549 — intervention group
Group type: EXPERIMENTAL
Intervention: EchiTAb Plus-ICP (ET-Plus)
Number of subjects: 400
Study 20668549 — intervention group
Group type: COMPARATOR
Intervention: EchiTAb G (ET-G)
Number of subjects: 400
Study 17327787 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 23
Study 17327787 — intervention group
Group type: COMPARATOR
Intervention: Surgical clipping
Number of subjects: 23
Study 14751423 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2 inhalation
Number of subjects: 20
Study 14751423 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhalation
Number of subjects: 20
Study 11801808 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg ex‐MLT
Number of subjects: 6
Study 11801808 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg ex‐MLT
Number of subjects: 6
Study 11801808 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg ex‐MLT
Number of subjects: 6
Study 11801808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 9580172 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic administration
Number of subjects: 733
Study 9580172 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 733
Study 8112231 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (150 mg daily for children < 20 kg; 300 mg daily for others)
Number of subjects: 84
Study 8112231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 8112231 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 84
Study 3381783 — intervention group
Group type: EXPERIMENTAL
Intervention: CME intervention: tutorial plus printed materials
Number of subjects: 90
Study 3381783 — intervention group
Group type: EXPERIMENTAL
Intervention: CME intervention: mailed printed materials only
Number of subjects: 90
Study 3381783 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 3381783 — intervention group
Group type: EXPERIMENTAL
Intervention: CME interventions (both types)
Number of subjects: 90
Study 31453617 — intervention group
Group type: EXPERIMENTAL
Intervention: α-lipoic acid (600 mg per day)
Number of subjects: 12
Study 31453617 — intervention group
Group type: COMPARATOR
Intervention: Placebo (600 mg cellulose per day)
Number of subjects: 12
Study 30282392 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib
Number of subjects: 94
Study 30282392 — intervention group
Group type: COMPARATOR
Intervention: 0.9% normal saline solution (placebo)
Number of subjects: 94
Study 26757368 — intervention group
Group type: COMPARATOR
Intervention: Anodal transcranial direct current stimulation (tDCS) applied to the primary somatosensory cortex (S1) over five days.
Number of subjects: 0
Study 26757368 — intervention group
Group type: COMPARATOR
Intervention: Sham application of tDCS.
Number of subjects: 0
Study 26757368 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS followed by functional magnetic resonance imaging (fMRI) assessments.
Number of subjects: 0
Study 25112175 — intervention group
Group type: EXPERIMENTAL
Intervention: L-tryptophan, 1 g orally three times a day for up to 3 days postoperatively
Number of subjects: 325
Study 25112175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 22566583 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAMcare intervention (multicondition collaborative treatment program)
Number of subjects: 214
Study 22566583 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 214
Study 20826416 — intervention group
Group type: EXPERIMENTAL
Intervention: Team Functioning Survey (TFS) scales
Number of subjects: 365
Study 20826416 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised scales from the TFS
Number of subjects: 365
Study 17883296 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin 100 mg administered 2 hours prior to ERCP
Number of subjects: 150
Study 17883296 — intervention group
Group type: COMPARATOR
Intervention: Rectal glycerin (control group)
Number of subjects: 150
Study 16631259 — intervention group
Group type: EXPERIMENTAL
Intervention: CD24 Ala/Val polymorphism
Number of subjects: 2348
Study 16631259 — intervention group
Group type: COMPARATOR
Intervention: Control group (unrelated and family‐based controls)
Number of subjects: 2348
Study 14597376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine
Number of subjects: 0
Study 14597376 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccine in children without older siblings attending day-care at 24 months
Number of subjects: 0
Study 10561226 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard alloBMT
Number of subjects: 840
Study 10561226 — intervention group
Group type: COMPARATOR
Intervention: IFNalpha therapy
Number of subjects: 840
Study 10561226 — intervention group
Group type: COMPARATOR
Intervention: Conventional chemotherapy (CHT)
Number of subjects: 840
Study 8741040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTXF) 5 mg/kg per hour for 6 hours for 3 successive days
Number of subjects: 29
Study 8741040 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 29
Study 8741040 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTXF)
Number of subjects: 29
Study 1841918 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate maintained at 100-110 beats/min (Group A)
Number of subjects: 105
Study 1841918 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate maintained at 90-100% of anaerobic threshold (Group B)
Number of subjects: 105
Study 7116299 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral melphalan (0.15 mg/kg/day for seven days, followed by 0.05 mg/kg/day after recovery from the nadir of the leukocytes) + Prednisone (0.8 mg/kg for the first two weeks, tapering over six weeks)
Number of subjects: 361
Study 7116299 — intervention group
Group type: COMPARATOR
Intervention: BCNU (150 mg/m2 intravenously every six weeks) + Prednisone (0.8 mg/kg for the first two weeks, tapering over six weeks)
Number of subjects: 361
Study 7116299 — intervention group
Group type: COMPARATOR
Intervention: CCNU (100 mg/m2 orally every six weeks) + Prednisone (0.8 mg/kg for the first two weeks, tapering over six weeks)
Number of subjects: 361
Study 7116299 — intervention group
Group type: EXPERIMENTAL
Intervention: Vincristine (1 mg/m2) + Prednisone (0.6 mg/kg for seven days) every two months (added at week 22)
Number of subjects: 361
Study 7116299 — intervention group
Group type: EXPERIMENTAL
Intervention: Good-risk patients treated with oral melphalan
Number of subjects: 361
Study 30864815 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor nighttime wind turbine noise (WTN) exposure
Number of subjects: 583968
Study 30864815 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor nighttime wind turbine noise (WTN) exposure (highest exposure group)
Number of subjects: 583968
Study 30864815 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor nighttime low-frequency wind turbine noise (LF WTN) exposure (highest exposure group)
Number of subjects: 583968
Study 29048765 — intervention group
Group type: EXPERIMENTAL
Intervention: Ageratum conyzoides extract at a dose of 250 mg/d, q.d. for 12 weeks
Number of subjects: 109
Study 29048765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 24633440 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcricoid lignocaine injection
Number of subjects: 0
Study 24439313 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (multidrug for at least four courses recommended)
Number of subjects: 162
Study 24439313 — intervention group
Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 162
Study 22625863 — intervention group
Group type: EXPERIMENTAL
Intervention: ProTaper (PT) files used in reciprocating motion
Number of subjects: 60
Study 22625863 — intervention group
Group type: COMPARATOR
Intervention: ProTaper (PT) files used in continuous rotary motion
Number of subjects: 60
Study 22625863 — intervention group
Group type: COMPARATOR
Intervention: Twisted Files (TF) used in continuous rotary motion
Number of subjects: 60
Study 20021401 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency transcutaneous sensory nerve stimulation (LF‐SNS) for 5 minutes, twice daily for up to 12 weeks
Number of subjects: 29
Study 20021401 — intervention group
Group type: COMPARATOR
Intervention: Sham nerve stimulation
Number of subjects: 29
Study 21179755 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement designed for high altitude
Number of subjects: 40
Study 21179755 — intervention group
Group type: COMPARATOR
Intervention: Stir-fried flour supplement (Control)
Number of subjects: 40
Study 13680141 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN), 10 mg daily
Number of subjects: 134
Study 13680141 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (AC), 1 microg daily
Number of subjects: 134
Study 11481083 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel treatment
Number of subjects: 6
Study 10424695 — intervention group
Group type: EXPERIMENTAL
Intervention: Right hemisphere for spatial judgments
Number of subjects: 2
Study 10424695 — intervention group
Group type: EXPERIMENTAL
Intervention: Left hemisphere for identity judgments
Number of subjects: 2
Study 7596131 — intervention group
Group type: EXPERIMENTAL
Intervention: DL-nebivolol 5 mg once daily for 4 weeks
Number of subjects: 30
Study 7596131 — intervention group
Group type: EXPERIMENTAL
Intervention: D-nebivolol 2.5 mg once daily for 4 weeks
Number of subjects: 30
Study 7596131 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 2248813 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 0.1 mg kg‐1
Number of subjects: 40
Study 2248813 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 2 mg kg‐1
Number of subjects: 40
Study 2248813 — intervention group
Group type: EXPERIMENTAL
Intervention: metoclopramide 0.1 mg kg‐1 with ranitidine 2 mg kg‐1
Number of subjects: 40
Study 2248813 — intervention group
Group type: COMPARATOR
Intervention: no premedication
Number of subjects: 40
Study 6989292 — intervention group
Group type: EXPERIMENTAL
Intervention: (+)-ketamine (PK), 1 mg/kg
Number of subjects: 60
Study 6989292 — intervention group
Group type: EXPERIMENTAL
Intervention: (−)-ketamine (MK), 3 mg/kg
Number of subjects: 60
Study 6989292 — intervention group
Group type: EXPERIMENTAL
Intervention: racemic ketamine (RK), 2 mg/kg
Number of subjects: 60
Study 31206433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2-3 µg·kg) administered approximately 1 hour before MRI
Number of subjects: 50
Study 30621614 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (titrated doses of 20 to 60 μg following a 3 h on + 1 h off regimen up to a maximum of 24 h)
Number of subjects: 3
Study 30621614 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (25 μg every 4 h up to a maximum of 24 h)
Number of subjects: 3
Study 30621614 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal dinoprostone (10 mg via controlled-release vaginal insert for up to 24 h)
Number of subjects: 3
Study 28656353 — intervention group
Group type: EXPERIMENTAL
Intervention: Low tidal volume with PEEP (TV, 5-7 ml/kg; PEEP, 4-6 cmH2O)
Number of subjects: 60
Study 28656353 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (TV, 8-10 ml/kg; PEEP, 0 cmH2O)
Number of subjects: 60
Study 28656353 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 24491348 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly structured exercise training (ET) for 12 weeks
Number of subjects: 106
Study 24491348 — intervention group
Group type: COMPARATOR
Intervention: Exercise advice (control)
Number of subjects: 106
Study 23926207 — intervention group
Group type: EXPERIMENTAL
Intervention: Visit-to-visit variability in systolic blood pressure (SBP)
Number of subjects: 8811
Study 23926207 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum systolic blood pressure (SBP)
Number of subjects: 8811
Study 20455192 — intervention group
Group type: EXPERIMENTAL
Intervention: Swivel seat
Number of subjects: 10
Study 20455192 — intervention group
Group type: COMPARATOR
Intervention: Fixed seat
Number of subjects: 10
Study 18363576 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA)
Number of subjects: 414
Study 18363576 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 414
Study 16404566 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct radiography (DR) at 50% dose
Number of subjects: 50
Study 16404566 — intervention group
Group type: COMPARATOR
Intervention: Computed radiography (CR) at regular dose
Number of subjects: 50
Study 16404566 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct radiography (DR) at regular dose
Number of subjects: 50
Study 16404566 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct radiography (DR) at reduced dose
Number of subjects: 50
Study 14686266 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational Music-making (RMM) protocol (6 sessions)
Number of subjects: 112
Study 14686266 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic impact analysis
Number of subjects: 112
Study 11192961 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A - discharged after remission of signs and symptoms
Number of subjects: 167
Study 11192961 — intervention group
Group type: COMPARATOR
Intervention: Group B - discharged after improvement but before complete remission of signs and symptoms
Number of subjects: 167
Study 8832118 — intervention group
Group type: EXPERIMENTAL
Intervention: Explaining conversation rules (I‐don't‐know is acceptable, interviewer cannot help)
Number of subjects: 114
Study 8832118 — intervention group
Group type: COMPARATOR
Intervention: Control group (no explanation of conversation rules)
Number of subjects: 114
Study 1466464 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 MAC isoflurane
Number of subjects: 8
Study 1466464 — intervention group
Group type: COMPARATOR
Intervention: Carrier gas (control)
Number of subjects: 8
Study 4045717 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine gum (2 mg)
Number of subjects: 0
Study 4045717 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 0
Study 4045717 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketed nicotine gum
Number of subjects: 0
Study 4045717 — intervention group
Group type: COMPARATOR
Intervention: New nicotine gum (less side-effects)
Number of subjects: 0
Study 4045717 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum (with more side-effects)
Number of subjects: 0
Study 31078351 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants in the DANAMI-3 trial (n = 179)
Number of subjects: 796
Study 31078351 — intervention group
Group type: COMPARATOR
Intervention: Eligible excluded (n = 144)
Number of subjects: 796
Study 31078351 — intervention group
Group type: COMPARATOR
Intervention: Ineligible excluded (n = 472)
Number of subjects: 796
Study 31078351 — intervention group
Group type: COMPARATOR
Intervention: Eligible non-screened (n = 154)
Number of subjects: 796
Study 31078351 — intervention group
Group type: COMPARATOR
Intervention: Ineligible non-screened (n = 154)
Number of subjects: 796
Study 28752433 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF-RHO (5-50 μg/kg)
Number of subjects: 0
Study 28752433 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF-RHO (5-30 μg/kg)
Number of subjects: 0
Study 28752433 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF-RHO (50 μg/kg)
Number of subjects: 0
Study 28752433 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim (6 mg, equivalent to 80-100 μg/kg)
Number of subjects: 0
Study 28752433 — intervention group
Group type: EXPERIMENTAL
Intervention: ANF-RHO
Number of subjects: 0
Study 28101914 — intervention group
Group type: EXPERIMENTAL
Intervention: Low cortisol (300 ng mL-1)
Number of subjects: 3
Study 28101914 — intervention group
Group type: EXPERIMENTAL
Intervention: High cortisol (1,000 ng mL-1)
Number of subjects: 3
Study 28101914 — intervention group
Group type: COMPARATOR
Intervention: Control (0 ng mL-1)
Number of subjects: 3
Study 25252663 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive tactile stimulation (two daily sessions of 30 minutes each for six months)
Number of subjects: 8
Study 25252663 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive tactile stimulation
Number of subjects: 8
Study 22980174 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining apical patency with a no. 10 K-file 1 mm beyond the working length (WL)
Number of subjects: 43
Study 22980174 — intervention group
Group type: COMPARATOR
Intervention: No patency (NP)
Number of subjects: 43
Study 20181361 — intervention group
Group type: EXPERIMENTAL
Intervention: LI160 (600 mg)
Number of subjects: 200
Study 20181361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 17570881 — intervention group
Group type: EXPERIMENTAL
Intervention: Case management group
Number of subjects: 67
Study 17570881 — intervention group
Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 67
Study 17681347 — intervention group
Group type: EXPERIMENTAL
Intervention: CoQ10 supplementation (100mg/day)
Number of subjects: 49
Study 17681347 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 15036741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (4ml/kg, 1.8meq./kg over 3-5min)
Number of subjects: 55
Study 15036741 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose (4ml/kg at similar rate)
Number of subjects: 55
Study 15036741 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Number of subjects: 55
Study 15036741 — intervention group
Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 55
Study 11212131 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNbeta‐1a (Avonex)
Number of subjects: 160
Study 11212131 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in BPF
Number of subjects: 160
Study 9054795 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training for deficit syndrome
Number of subjects: 6
Study 9054795 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training for nondeficit negative symptoms
Number of subjects: 6
Study 8347969 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic epidural blockade with local anaesthetic
Number of subjects: 100
Study 8347969 — intervention group
Group type: COMPARATOR
Intervention: Saline injection into the epidural space
Number of subjects: 100
Study 3519043 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 60 mg
Number of subjects: 10
Study 3519043 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 90 mg
Number of subjects: 10
Study 3519043 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil 120 mg
Number of subjects: 10
Study 3519043 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil
Number of subjects: 10
Study 3519043 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31340204 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 117
Study 31340204 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group is OMT)
Number of subjects: 117
Study 29898059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 200 mg + Omeprazole 20 mg (once daily - q.d.)
Number of subjects: 50
Study 29898059 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen 100 mg (twice daily - b.i.d.)
Number of subjects: 50
Study 27701019 — intervention group
Group type: EXPERIMENTAL
Intervention: Payment Card (PC)
Number of subjects: 376
Study 27701019 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Haggling (SH)
Number of subjects: 376
Study 22006639 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine (0.4 mg, i.v.)
Number of subjects: 15
Study 22006639 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 15
Study 19459752 — intervention group
Group type: EXPERIMENTAL
Intervention: Camel milk (500 mL daily)
Number of subjects: 54
Study 19459752 — intervention group
Group type: COMPARATOR
Intervention: Usual management (diet, exercise, and insulin)
Number of subjects: 54
Study 17257536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate (1.0 ml)
Number of subjects: 37